Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859761 | 0.82 | HRH2 (0.48) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL5204952 | 0.81 | HRH2 (0.55) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL5206068 | 0.81 | LMNA (0.49) | HRH2HTR2AHTR2CHTR2BTHRB | |
| SCHEMBL27559062 | 0.77 | HRH2 (0.59) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL5205873 | 0.77 | HRH2 (0.51) | HRH2HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL5205803 | 0.76 | HRH2 (0.50) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL4849757 | 0.73 | HRH2 (0.47) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL27478068 | 0.73 | HRH2 (0.55) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL5201671 | 0.71 | ALDH1A1 (0.51) | HRH2HTR2AHTR2CHTR2BTPSAB1 | |
| SCHEMBL5799049 | 0.71 | HRH2 (0.44) | HRH2HTR2AHTR2CHTR2BTPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | OPRD1, OPRK1, TPH1 | HRH2 973/4885HTR2A 12/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.